This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 2006-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006-2014
Title: Patricia Smirnoff: Innovator in Cell Proliferation Inhibition
Introduction
Patricia Smirnoff is a distinguished inventor based in Rehovot, Israel. She has made significant contributions to the field of cell biology, particularly in the area of inhibiting the proliferation of mammalian cells. With a total of 6 patents to her name, her work has the potential to impact therapeutic approaches in various medical conditions.
Latest Patents
Among her latest patents, Patricia has developed methods and compositions for inhibiting the proliferation of mammalian cells. One notable method involves preventing, inhibiting, and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation, and/or development of abnormal cells in a subject. This method is achieved by administering a therapeutically effective amount of a ribonuclease of the T2 family that possesses actin binding activity.
Career Highlights
Patricia is affiliated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Her innovative research has garnered attention in the scientific community, showcasing her dedication to advancing knowledge in her field.
Collaborations
Throughout her career, Patricia has collaborated with notable colleagues, including Betty Schwartz and Oded Shoseyov. These partnerships have further enriched her research endeavors and contributed to her success as an inventor.
Conclusion
Patricia Smirnoff's work in cell proliferation inhibition exemplifies the impact of innovative research in medicine. Her contributions continue to pave the way for advancements in therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
